Quote | QSAM Biosciences Inc (OTCMKTS:QSAM)
Last: | $8.30 |
---|---|
Change Percent: | 6.63% |
Open: | $7.75 |
Close: | $8.30 |
High: | $8.3 |
Low: | $7.744 |
Volume: | 133,563 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | QSAM Biosciences Inc (OTCMKTS:QSAM)
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
2024-04-16 08:42:16 ET More on QSAM Biosciences QSAM to be acquired by Telix for $33.1M plus $90M CVR Financial information for QSAM Biosciences Read the full article on Seeking Alpha For further details see: QSAM Biosciences to implement a 1-for-2,000 re...
Message Board Posts | QSAM Biosciences Inc (OTCMKTS:QSAM)
Subject | By | Source | When |
---|---|---|---|
No celebration just yet Bobbychucky, but the news | logytwo | investorshub | 04/29/2023 2:09:10 AM |
No reason to be around... while you are | ChuckFinley305 | investorshub | 04/28/2023 1:02:30 PM |
Chuckybobby where you at man, been awful quiet. | logytwo | investorshub | 04/26/2023 1:22:41 PM |
$QSAM Biosciences Receives Second Key Patent in Europe | logytwo | investorshub | 04/26/2023 1:20:45 PM |
04/05/2023 $QSAM Biosciences Opens Enrollment of the Second Cohort | logytwo | investorshub | 04/05/2023 11:43:37 PM |
News, Short Squeeze, Breakout and More Instantly...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc . (OTCQB: QSAM) (“ QSAM ” or the “ Company ”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par...
QSAM Biosciences (OTCQB: QSAM) , a clinical-stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam), for the treatment of bone cancer and other diseases and conditions, has signed a definitive agreement and plan of merger pr...